AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, developer of Deciparticle ™, today announced it received approval from Australia’s Human Research Ethics Committee (HREC) to begin ...
Oncotelic Therapeutics Inc.'s (OTCQB: OTLC) Sapu Nano joint venture is making progress with Sapu003, its intravenous Deciparticle formulation of everolimus, the powerful drug to fight cancer and ...
SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Sapu Nano today announced the presentation of its poster, “Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 Study in ...
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results